A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer

By Kang Yoon-Koo   Muro Kei   Ryu Min-Hee   Yasui Hirofumi   Nishina Tomohiro   Ryoo Baek-Yeol   Kamiya Yukimasa   Akinaga Shiro   Boku Narikazu  

Investigational New Drugs, Vol. 32, Iss. 2, 2014-04 ,pp. : 355-361

Springer Publishing Company

Access to resources Recommend Favorite

Enhancement of the Antiproliferative Activity of Gemcitabine by Modulation of c-Met Pathway in Pancreatic Cancer

By  

Current Pharmaceutical Design, Vol. 19, Iss. 5, 2013-02 ,pp. : 940-950

Bentham Science Publishers

Access to resources Recommend Favorite

Development of c-MET pathway inhibitors

By Liu Xiangdong   Newton Robert C   Scherle Peggy A  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 9, 2011-09 ,pp. : 1225-1241

Informa Healthcare

Access to resources Recommend Favorite

Inhibition of c-Met with the Specific Small Molecule Tyrosine Kinase Inhibitor SU11274 Decreases Growth and Metastasis Formation of Experimental Human Melanoma

By  

Current Cancer Drug Targets, Vol. 10, Iss. 3, 2010-05 ,pp. : 332-342

Bentham Science Publishers

Access to resources Recommend Favorite

Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice

By Colon Jimmie   Basha Md.   Madero-Visbal Rafael   Konduri Santhi   Baker Cheryl   Herrera Luis   Safe Stephen   Sheikh-Hamad David   Abudayyeh Ala   Alvarado Beatrice   Abdelrahim Maen  

Investigational New Drugs, Vol. 29, Iss. 1, 2011-02 ,pp. : 41-51

Springer Publishing Company

Access to resources Recommend Favorite